Comprehensive Predictors of Drug-resistant Epilepsy in MELAS: Clinical, EEG, Imaging, and Biochemical Factors

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2025 Feb 14

PMID 39953503

Authors

Rui Gao

Lihua Gu

Wenchao Zuo

Pan Wang

Affiliations

Soon will be listed here.

Abstract

Background: Seizures are a common but often overlooked manifestation of MELAS. This study aimed to describe the characteristics of seizures in MELAS and to analyze the clinical, electroencephalographic, imaging, and biochemical factors associated with drug-resistant epilepsy.

Methods: A single-center retrospective study was conducted to investigate the clinical characteristics of seizures in MELAS patients. The study collected data on clinical features, muscle biopsy results, genetic testing, seizure symptoms, electroencephalography (EEG), neuroimaging findings, cerebrospinal fluid and blood biochemistry, and the modified Rankin Scale (mRS). We also investigated the correlation between seizure frequency and mRS scores. In addition, we analyzed the risk factors for drug-resistant epilepsy in MELAS.

Results: A total of 37 patients with confirmed MELAS (24 males and 13 females) were included in the study. All patients experienced seizures, with an onset age ranging from 14 to 53 years and a mean of 32 years. These MELAS patients experienced a variety of seizure types, with generalized seizures being the most common. EEG findings revealed background rhythm abnormalities in all patients, and epileptiform discharges were observed in 37.8% of patients during the interictal phase. Status epilepticus (OR 16.499; 95% CI, 1.615-168.557; P = 0.018) and elevated resting serum lactate levels (OR 8.594; 95% CI, 1.342-59.733; P = 0.024) were identified as independent risk factors for drug-resistant epilepsy. In addition, changes in the seizure frequency at the last follow-up compared to baseline were positively correlated with the mRS score. (r = 0.533, p < 0.001).

Conclusion: Status epilepticus and elevated resting serum lactate levels were predictive of the development of drug-resistant epilepsy in MELAS. Poor seizure control was significantly associated with increased clinical disability. Early identification of high-risk patients for drug-resistant epilepsy could facilitate the development of more effective treatment plans.

References

Susse M, Gag K, Hamann L, Hannich M, von Podewils F . Time dependency of CSF cell count, lactate and blood-CSF barrier dysfunction after epileptic seizures and status epilepticus. Seizure. 2021; 95:11-16. DOI: 10.1016/j.seizure.2021.12.007. View

Finsterer J, Zarrouk-Mahjoub S . Focal and Generalized Seizures May Occur in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike Episodes (MELAS) Patients. J Child Neurol. 2015; 30(11):1553-4. DOI: 10.1177/0883073814567539. View

Wang W, Sun Y, Lin Y, Xu X, Zhao D, Ji K . A novel nonsense variant in MT-CO3 causes MELAS syndrome. Neuromuscul Disord. 2021; 31(6):558-565. DOI: 10.1016/j.nmd.2021.02.020. View

Bindu P, Sonam K, Govindaraj P, Govindaraju C, Chiplunkar S, Nagappa M . Outcome of epilepsy in patients with mitochondrial disorders: Phenotype genotype and magnetic resonance imaging correlations. Clin Neurol Neurosurg. 2017; 164:182-189. DOI: 10.1016/j.clineuro.2017.12.010. View

Chevallier J, Von Allmen G, Koenig M . Seizure semiology and EEG findings in mitochondrial diseases. Epilepsia. 2014; 55(5):707-712. DOI: 10.1111/epi.12570. View

Fan H, Lee H, Yue C, Chi C . Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. Life (Basel). 2021; 11(11). PMC: 8617702. DOI: 10.3390/life11111111. View

Gramegna L, Evangelisti S, Di Vito L, La Morgia C, Maresca A, Caporali L . Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations. Ann Clin Transl Neurol. 2021; 8(6):1200-1211. PMC: 8164862. DOI: 10.1002/acn3.51329. View

Fisher R . An overview of the 2017 ILAE operational classification of seizure types. Epilepsy Behav. 2017; 70(Pt A):271-273. DOI: 10.1016/j.yebeh.2017.03.022. View

Xue-Ping W, Hai-Jiao W, Li-Na Z, Xu D, Ling L . Risk factors for drug-resistant epilepsy: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(30):e16402. PMC: 6708813. DOI: 10.1097/MD.0000000000016402. View

10.

Ji K, Ren H, Zhao X, Yan C . Migratory Rolandic Encephalopathy Caused by the Mitochondrial Variant. Neurology. 2021; 98(2):80-81. DOI: 10.1212/WNL.0000000000013015. View

11.

Boguszewicz L, Jamroz E, Ciszek M, Emich-Widera E, Kijonka M, Banasik T . NMR-based metabolomics in pediatric drug resistant epilepsy - preliminary results. Sci Rep. 2019; 9(1):15035. PMC: 6803684. DOI: 10.1038/s41598-019-51337-z. View

12.

Berg A, Shinnar S, Levy S, Testa F, Beckerman B . Early development of intractable epilepsy in children: a prospective study. Neurology. 2001; 56(11):1445-52. DOI: 10.1212/wnl.56.11.1445. View

13.

Krysko K, Sundaram A . Recurrent Alternate-Sided Homonymous Hemianopia Due to Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report. Neuroophthalmology. 2017; 41(1):30-34. PMC: 5278788. DOI: 10.1080/01658107.2016.1224256. View

14.

Gibbs J, Walker M, Cock H . Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia. 2006; 47(3):469-78. DOI: 10.1111/j.1528-1167.2006.00454.x. View

15.

Fujimoto S, Mizuno K, Shibata H, Kanayama M, Kobayashi M, Sugiyama N . Serial electroencephalographic findings in patients with MELAS. Pediatr Neurol. 1999; 20(1):43-8. DOI: 10.1016/s0887-8994(98)00088-5. View

16.

Patel J, Tran Q, Martinez S, Wright H, Pourmand A . Utility of serum lactate on differential diagnosis of seizure-like activity: A systematic review and meta-analysis. Seizure. 2022; 102:134-142. DOI: 10.1016/j.seizure.2022.10.007. View

17.

Fattorusso A, Matricardi S, Mencaroni E, DellIsola G, Di Cara G, Striano P . The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies. Front Neurol. 2021; 12:674483. PMC: 8258148. DOI: 10.3389/fneur.2021.674483. View

18.

Hay A, Bellomo R, Pilcher D, Jackson G, Kaukonen K, Bailey M . Characteristics and outcome of patients with the ICU Admission diagnosis of status epilepticus in Australia and New Zealand. J Crit Care. 2016; 34:146-53. DOI: 10.1016/j.jcrc.2016.03.003. View

19.

Zsurka G, Kunz W . Mitochondrial dysfunction and seizures: the neuronal energy crisis. Lancet Neurol. 2015; 14(9):956-66. DOI: 10.1016/S1474-4422(15)00148-9. View

20.

Hirano M, Emmanuele V, Quinzii C . Emerging therapies for mitochondrial diseases. Essays Biochem. 2018; 62(3):467-481. PMC: 6104515. DOI: 10.1042/EBC20170114. View